Protection against porcine reproductive and respiratory syndrome virus (PRRSV) infection through passive transfer of PRRSV-neutralizing antibodies is dose dependent.
about
Review on the transmission porcine reproductive and respiratory syndrome virus between pigs and farms and impact on vaccinationPorcine reproductive and respiratory syndrome (PRRS): an immune dysregulatory pandemic.Porcine Reproductive and Respiratory Syndrome Virus Utilizes Nanotubes for Intercellular SpreadMechanisms of Adaptive Immunity to Porcine Reproductive and Respiratory Syndrome VirusPathogenesis and antigenic characterization of a new East European subtype 3 porcine reproductive and respiratory syndrome virus isolate.Immune responses in mice vaccinated with virus-like particles composed of the GP5 and M proteins of porcine reproductive and respiratory syndrome virus.Comparison of the efficacy of autogenous inactivated Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) vaccines with that of commercial vaccines against homologous and heterologous challenges.Signal peptide cleavage from GP5 of PRRSV: a minor fraction of molecules retains the decoy epitope, a presumed molecular cause for viral persistence.Broadening the heterologous cross-neutralizing antibody inducing ability of porcine reproductive and respiratory syndrome virus by breeding the GP4 or M genes.Immune evasion of porcine reproductive and respiratory syndrome virus through glycan shielding involves both glycoprotein 5 as well as glycoprotein 3.Does Circulating Antibody Play a Role in the Protection of Piglets against Porcine Epidemic Diarrhea Virus?Recognition of Highly Diverse Type-1 and -2 Porcine Reproductive and Respiratory Syndrome Viruses (PRRSVs) by T-Lymphocytes Induced in Pigs after Experimental Infection with a Type-2 PRRSV Strain.A Synthetic Porcine Reproductive and Respiratory Syndrome Virus Strain Confers Unprecedented Levels of Heterologous Protection.Construction and immunogenicity of a recombinant swinepox virus expressing a multi-epitope peptide for porcine reproductive and respiratory syndrome virusComparative analysis of routes of immunization of a live porcine reproductive and respiratory syndrome virus (PRRSV) vaccine in a heterologous virus challenge study.Immunogenic and protective properties of GP5 and M structural proteins of porcine reproductive and respiratory syndrome virus expressed from replicating but nondisseminating adenovectors.Development and validation of an assay to detect porcine reproductive and respiratory syndrome virus-specific neutralizing antibody titers in pig oral fluid samples.Evaluation of the Cross-Protective Efficacy of a Chimeric Porcine Reproductive and Respiratory Syndrome Virus Constructed Based on Two Field Strains.Sustaining Interferon Induction by a High-Passage Atypical Porcine Reproductive and Respiratory Syndrome Virus StrainVaccination of sows against type 2 Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) before artificial insemination protects against type 2 PRRSV challenge but does not protect against type 1 PRRSV challenge in late gestationAssessment of the efficacy of two novel DNA vaccine formulations against highly pathogenic Porcine Reproductive and Respiratory Syndrome Virus.Micro-dissecting the pathogenesis and immune response of PRRSV infection paves the way for more efficient PRRSV vaccines.Mucosal vaccines to prevent porcine reproductive and respiratory syndrome: a new perspective.Positive effects of porcine IL-2 and IL-4 on virus-specific immune responses induced by the porcine reproductive and respiratory syndrome virus (PRRSV) ORF5 DNA vaccine in swineImmune Control of PRRS: Lessons to be Learned and Possible Ways Forward.Challenges in Veterinary Vaccine Development and Immunization.Effector mechanisms of humoral immunity to porcine reproductive and respiratory syndrome virus.Evaluation of the efficacy of an attenuated live vaccine against highly pathogenic porcine reproductive and respiratory syndrome virus in young pigs.Immunopotentiation of four natural adjuvants co-administered with a highly pathogenic porcine reproductive and respiratory syndrome virus glycoprotein 5 subunit.A variable region in GP4 of European-type porcine reproductive and respiratory syndrome virus induces neutralizing antibodies against homologous but not heterologous virus strains.Immune responses in pigs induced by recombinant DNA vaccine co-expressing swine IL-18 and membrane protein of porcine reproductive and respiratory syndrome virus.Characterization of homologous and heterologous adaptive immune responses in porcine reproductive and respiratory syndrome virus infectionFresh Pork and Porcine Reproductive and Respiratory Syndrome Virus: Factors Related to the Risk of Disease Transmission.Construction and immunogenicity of DNA vaccines encoding fusion protein of porcine IFN- λ 1 and GP5 gene of porcine reproductive and respiratory syndrome virus.Immunogenicity of recombinant vaccinia virus vaccines co-expressing GP3/GP5 of European PRRSV and Cap protein of PCV2 in pigs.Exosomes mediate intercellular transmission of porcine reproductive and respiratory syndrome virus (PRRSV).Porcine reproductive and respiratory syndrome virus neutralizing antibodies provide in vivo cross-protection to PRRSV1 and PRRSV2 viral challenge.Recent advances in veterinary applications of structural vaccinology.Vaccination of piglets at 2 and 3 weeks of age with Ingelvac PRRSFLEX® EU provides protection against heterologous field challenge in the face of homologous maternally derived antibodies.Pigs that recover from porcine reproduction and respiratory syndrome virus infection develop cytotoxic CD4+CD8+ and CD4+CD8- T-cells that kill virus infected cells
P2860
Q28071014-437441BB-90C6-4833-BE7F-C403116F3287Q30364184-41CCAF2F-FE74-43BF-86DD-6B9C687C12CEQ30754418-684A0EEF-2641-4E2F-B96D-E29547BAE839Q32183108-B38B4168-98E0-4501-A983-FFC756BC1D67Q33595227-16DA0728-6C30-40C1-A9D5-2BC7EB3E899CQ34019891-FA99617B-89C7-44D2-A554-CC9E075DDD3FQ34432119-707BB738-F9A1-4000-ACF2-153A7E47EE85Q34766625-7A570CA0-05F0-4E76-9FA5-9A08FAB94758Q34795790-E3F45523-54F1-4BE0-8ACE-4C5388D2BE24Q34982599-E2CBE26A-AF0B-4219-818C-32162DB80907Q35981194-60F061AF-B83E-45CF-A333-3521F33DFDFCQ36178539-28606D1B-E261-4129-8829-82DF33D8D20DQ36281179-0228DB0E-859F-4A91-8C2A-62DC36DD29CEQ36300502-37A31CCD-10EC-43C1-8D98-38476938E3BDQ36700988-8802E1DE-DD94-4758-9C77-CA102CC79D3CQ36715877-65481255-6DCF-4C52-B9D2-D8C94F536D62Q37124781-3DC9508A-3D8C-44A6-9D41-53F13764DB31Q37203209-038DA5D7-0AAD-4CCD-AAC9-D7B6775B61EBQ37387346-3282C71F-0538-4243-B554-CAB5A1148C1DQ37582096-6B625689-54A1-4850-B5E8-CADFA36FC8E8Q37623519-33A7D0D3-1E16-4FB7-AB9E-78413CC191D6Q37973836-59764572-81BC-4F41-8412-6B3E2439C1E2Q38020309-F1094DA8-4D7D-4E34-97C0-F30C936B10A0Q38597798-214243B8-B464-45A2-821F-FA975604FB70Q38668708-6B3E2EDD-4516-4F5C-B395-B540FC2B535AQ38807872-B282E3BD-138A-4FD2-9BF1-EB1B392D9CB7Q39245066-B40DCCF0-00D3-4F9F-B664-D2DBF60DA708Q39331846-F56A5C0E-69CF-4A4D-87AE-511CB34BA476Q40922501-8CF48EB0-A13E-4A2B-BA36-44D0816E27C1Q42085923-B7E631D4-A3C5-4369-99F8-3EB985FB9810Q42214065-6042BB3A-73D4-4463-B847-C3019BB65BA3Q42248007-222DD924-9439-4688-BB4D-17677C0C828CQ42248419-F8AC946C-8B7F-4027-8EF4-DDBF6BD39DBFQ44781644-ABD294AD-AB20-4130-AB28-601D0FB47057Q45324020-4EAFA48A-EBF8-45BA-94D1-7B28BBE36935Q45324062-4BEA9D5A-9E82-4A2F-8A9A-B63C072DCD11Q50166841-A200597A-21BA-4E54-B58A-15A721D3A060Q52650429-2E6A42BC-D89A-4AAB-96A8-9EF657F3BAB6Q53729326-1E1119D3-081D-4B2A-9A01-42EDC9DD1F2BQ57160272-857CF083-5D78-4337-BE87-6CFDB5204EB2
P2860
Protection against porcine reproductive and respiratory syndrome virus (PRRSV) infection through passive transfer of PRRSV-neutralizing antibodies is dose dependent.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Protection against porcine rep ...... antibodies is dose dependent.
@ast
Protection against porcine rep ...... antibodies is dose dependent.
@en
type
label
Protection against porcine rep ...... antibodies is dose dependent.
@ast
Protection against porcine rep ...... antibodies is dose dependent.
@en
prefLabel
Protection against porcine rep ...... antibodies is dose dependent.
@ast
Protection against porcine rep ...... antibodies is dose dependent.
@en
P2093
P2860
P356
P1476
Protection against porcine rep ...... g antibodies is dose dependent
@en
P2093
E Alvarez Garcia
F A Osorio
M F Oliveira
P2860
P304
P356
10.1128/CVI.00304-06
P577
2007-01-10T00:00:00Z